Press release
Metastatic Melanoma Pipeline Outlook Report 2024 (Updated)
Metastatic Melanoma Pipeline
Key Takeaways from the Metastatic Melanoma Pipeline Report
• DelveInsight's Metastatic Melanoma pipeline report depicts a robust space with 75+ active players working to develop 75+ pipeline therapies for Metastatic Melanoma treatment.
• The leading companies working in the Metastatic Melanoma Market include Evaxion Biotech, InxMed, AiVita Biomedical, Iovance Biotherapeutics, Viralytics, Merck & Co., Neon Therapeutics, BioNTech, Bristol-Myers Squibb, Ono Pharmaceuticals, Cytovation AS, and others.
• Promising Metastatic Melanoma Pipeline Therapies in the various stages of development include TLPLDC Vaccine, EVX-01, Pembrolizumab 25 MG/ML, Nivolumab, IN10018, Cobimetinib, and others.
• March 2024: Elios Therapeutics LLC announced a study of Phase 1 & 2 clinical trials for TLPLDC Vaccine. Assess the safety and tumor response of utilizing an autologous tumor lysate, particle-loaded, dendritic cell (TLPLDC) vaccine given in combination with standard of care (SoC) checkpoint inhibitors (CPI) in patients with stage IV melanoma with measurable disease.
• March 2024: Massachusetts General Hospital announced a study of Phase 2 clinical trials for Pembrolizumab, Dabrafenib and Trametinib. This research study is studying a combination of drugs as a possible treatment for unresectable or metastatic melanoma. This research study is a Phase II clinical trial. Phase II clinical trials test the safety and effectiveness of an investigational drug to learn whether the drug works in treating a specific disease. "Investigational" means that the drug is being studied.
Request a sample and discover the recent advances in Metastatic Melanoma Treatment Drugs @ Metastatic Melanoma Pipeline Report- https://www.delveinsight.com/report-store/metastatic-melanoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
In the Metastatic Melanoma pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Metastatic Melanoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Metastatic Melanoma Overview
Melanoma is the third most common cutaneous malignancy after basal cell carcinoma and squamous cell carcinoma. Melanoma is the fifth most common malignancy in males and sixth most common malignancy in females. Metastatic melanoma is a disease that occurs when the cancerous cells from the original tumor (primary tumor) get loose, spread by traveling through the lymph or blood circulation, and start a new tumor (metastatic tumor) somewhere else.
Find out more about Metastatic Melanoma Therapeutics Assessment @ Metastatic Melanoma Preclinical and Discovery Stage Products- https://www.delveinsight.com/sample-request/metastatic-melanoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Metastatic Melanoma Emerging Drugs Profile
• EVX 01: Evaxion Biotech
• IN 10018: InxMed
• AV MEL 1: AiVita Biomedical
Metastatic Melanoma Pipeline Therapeutics Assessment
There are approx. 75+ key companies which are developing the Metastatic Melanoma therapies. The Metastatic Melanoma companies which have their Metastatic Melanoma drug candidates in the most advanced stage, i.e. Phase II, Evaxion Biotech.
DelveInsight's Metastatic Melanoma pipeline report covers around 75+ products under different phases of clinical development like
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
Metastatic Melanoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal
Metastatic Melanoma Pipeline Products have been categorized under various Molecule types such as
• Oligonucleotide
• Peptide
• Small molecule
Learn more about the emerging Metastatic Melanoma Pipeline Therapies @ Metastatic Melanoma Clinical Trials Assessment- https://www.delveinsight.com/sample-request/metastatic-melanoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Scope of the Metastatic Melanoma Pipeline Report
• Coverage- Global
• Metastatic Melanoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Metastatic Melanoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Metastatic Melanoma Companies- Evaxion Biotech, InxMed, AiVita Biomedical, Iovance Biotherapeutics, Viralytics, Merck & Co., Neon Therapeutics, BioNTech, Bristol-Myers Squibb, Ono Pharmaceuticals, Cytovation AS, and others.
• Metastatic Melanoma Pipeline Therapies- TLPLDC Vaccine, EVX-01, Pembrolizumab 25 MG/ML, Nivolumab, IN10018, Cobimetinib, and others.
Dive deep into rich insights for new drugs for Metastatic Melanoma Treatment, Visit @ Metastatic Melanoma Market Drivers and Barriers, and Future Perspective- https://www.delveinsight.com/sample-request/metastatic-melanoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Table of Content
1. Introduction
2. Executive Summary
3. Metastatic Melanoma: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Metastatic Melanoma- DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. Drug name: Company name
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. EVX 01: Evaxion Biotech
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. IN 10018: InxMed
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug name: Company name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Metastatic Melanoma Key Companies
21. Metastatic Melanoma Key Products
22. Metastatic Melanoma- Unmet Needs
23. Metastatic Melanoma- Market Drivers and Barriers
24. Metastatic Melanoma- Future Perspectives and Conclusion
25. Metastatic Melanoma Analyst Views
26. Metastatic Melanoma Key Companies
27. 27. Appendix
For further information on the Metastatic Melanoma Pipeline therapeutics, reach out to Metastatic Melanoma Unmet Needs and Analyst Views- https://www.delveinsight.com/sample-request/metastatic-melanoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
List of Important Links-
https://theventurecation.com/author/germanydennydones/
https://blogstudiio.com/fabry-disease-market-size/
https://meccapost.com/author/germanydennydones/
https://kitmaker.net/profile/yashveer-bhardwaj
http://www.costaricajobsearch.com/author/germanydennydones/
https://keralaclick.com/classified-advertising/user/profile/182882
https://aviator.forex.pm/?qa=user/germanydennydones
https://careers.coloradopublichealth.org/employers/2926283-delveinsight
https://www.heavyironjobs.com/profiles/4448319-denny-dones
https://jobs.blooloop.com/employers/2614577-delveinsight
https://www.animaljobsdirect.com/employers/2926436-delveinsight
https://jobs.windomnews.com/employers/2926467-delveinsight
https://jobs.fsoma.org/employers/2926471-delveinsight
https://jobs.thetab.com/employers/1458246-delveinsight
https://forum.squarespace.com/profile/421527-dennydonesgermany/?tab=field_core_pfield_1
https://camp-fire.jp/profile/germanydennydones
https://myaajkal.xyz/page/other/atopic-dermatitis-market-size/
https://talkotive.com/read-blog/136659
https://monstaluck.mn.co/posts/53508338
https://network-6063768.mn.co/posts/53508913
https://black-gun-association.mn.co/posts/53509422
https://charleston-wiffleball-association.mn.co/posts/53509543
https://network-6247558.mn.co/posts/53509666
https://franko-trading-enterprise.mn.co/posts/53509819
https://nordic-future.mn.co/posts/53509979
https://the-trifecta-network.mn.co/posts/53510053
https://diamond-members.mn.co/posts/53510731
https://tonow.mn.co/posts/53510860
https://network-1062788.mn.co/posts/53511032
https://d6united.mn.co/posts/53511102
https://mighty-networks-foundation.mn.co/posts/53511176
https://network-759413.mn.co/posts/53511779
https://walkinvirtualclinics.mn.co/posts/53511912
https://inbound-tourism-inner-circle.mn.co/posts/53512259
https://acertdglobalplatform.mn.co/posts/53512375
https://comidarealkitchen.mn.co/posts/53512492
https://ripple-xrp-global-network.mn.co/posts/understanding-the-atopic-dermatitis-market-size-forecast-and-outlook
https://facial546.mn.co/posts/53513294
https://moneyschoolinc.mn.co/posts/53513378
https://mylook-online.mn.co/posts/53513464
https://network-6063768.mn.co/posts/53513575
https://edpt200.mn.co/posts/53513922
https://decorated-with-members.mn.co/posts/53514022
https://fromfostercaretoceo.mn.co/posts/53514116
https://foodxtech.mn.co/posts/53514153
https://thinktrain.mn.co/posts/53514300
https://nc-cricket.mn.co/posts/53514349
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 9650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/medical-marijuana-market-insight
https://www.delveinsight.com/report-store/pelizaeus-merzbacher-disease-market
https://www.delveinsight.com/report-store/radial-artery-compression-devices-market
https://www.delveinsight.com/report-store/uk-healthcare-outlook-report
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Metastatic Melanoma Pipeline Outlook Report 2024 (Updated) here
News-ID: 3444228 • Views: …
More Releases from DelveInsight Business Research LLP
Genital Warts Pipeline Insights Report 2025 | DelveInsight
DelveInsight's, "Genital Warts Pipeline Insight 2025" report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Genital Warts pipeline landscape. It covers the Genital Warts pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore the comprehensive insights by DelveInsight and stay ahead…
Traumatic Brain Injury Pipeline Drugs Report 2025 | DelveInsight
DelveInsight's "Traumatic Brain Injury Pipeline Insight 2025" report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in Tthe raumatic Brain Injury pipeline landscape. It covers the Traumatic Brain Injury pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Traumatic Brain Injury pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore…
Bone Metastasis Pipeline Assessment Report 2025 | DelveInsight
DelveInsight's, "Bone Metastases Pipeline Insight, 2025," report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Bone Metastases pipeline landscape. It covers the Bone Metastasis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Bone Metastasis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore the comprehensive insights by DelveInsight…
Acquired Immunodeficiency Syndrome Treatment Market Size Report 2032 | DelveInsi …
DelveInsight's "Acquired Immunodeficiency Syndrome Market Insights, Epidemiology, and Market Forecast-2032′′ report offers an in-depth understanding of the Acquired Immunodeficiency Syndrome, historical and forecasted epidemiology as well as the Acquired Immunodeficiency Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
To Know in detail about the Acquired Immunodeficiency Syndrome market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Acquired Immunodeficiency Syndrome Market…
More Releases for Melanoma
Rising Incidence Of Melanoma Cases Boosts Metastatic Melanoma Therapeutics Marke …
The Metastatic Melanoma Therapeutics Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Expected Metastatic Melanoma Therapeutics Market Size During the Forecast Period?
The market size for therapeutics in metastatic melanoma has swiftly increased in the past few years. It is projected to augment…
Rising Incidence Of Melanoma Cases Boosts Metastatic Melanoma Therapeutics Marke …
What combination of drivers is leading to accelerated growth in the metastatic melanoma therapeutics market?
The growth of the metastatic melanoma therapeutics market is anticipated to be fueled by the increasing prevalence of melanoma cases. Melanoma, a type of skin cancer, originates in the cells, known as melanocytes, that determine the skin's pigment. Melanomas can develop on any part of the skin. Metastatic melanoma therapeutics comprise various treatments designed to interrupt…
Key Influencer in the Melanoma Therapeutics Market 2025: Surge In Melanoma Incid …
How Are the key drivers contributing to the expansion of the melanoma therapeutics market?
The rise in melanoma cases is predicted to fuel the expansion of the melanoma therapeutics market. Melanoma, a type of skin cancer, begins in the melanocytes. The therapies and medications used to treat melanoma patients and mitigate the effects of cancer are known as melanoma therapeutics. An increase in melanoma cases, therefore, leads to a surge in…
Skin Cancer Market By Cancer Type (Melanoma, Non-melanoma)
Most skin cancers are locally destructive malignant growth of the skin. They come from the epidermis cells, the skin's superficial layer. The vast majority of these types of skin cancers seldom spread (metastasize) to other areas of the body and become life-threatening, unlike cutaneous malignant melanoma.
Download Sample PDF at https://www.theinsightpartners.com/sample/TIPRE00018117/?utm_source=OpenPR&utm_medium=10379
Key Players Analysis:
• Pfizer Inc.
• Bristol-Myers Squibb Company
• Abbott Laboratories
• Amgen, Inc.
• Merck & Co., Inc.
• Novartis AG
• F. Hoffmann-La Roche Ltd
• Sanofi S.A.
• Qiagen NV
• Sun Pharmaceutical Industries Ltd…
Melanoma Diagnostics Market - Shining Light on Melanoma: Transforming Lives with …
Newark, New Castle, USA - new report, titled Melanoma Diagnostics Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Melanoma Diagnostics market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Melanoma Diagnostics market. The report offers an overview of the market, which…
Intraocular Melanoma Treatment Market Drivers
Neurological disorder diagnostics tools are medical devices, which are used in diagnosis of various neurological disorders such as Alzheimer’s disease (AD), Parkinson’s disease (PD), and Multiple Sclerosis. The devices which are majorly used in diagnosis are imaging tools such as Computed Tomography (CT), Magnetic Resonance Imaging (MRI), and in-vitro diagnostics tools such as biomarker and biopsy. Increasing prevalence of neurological disorders in the recent past has increased demand for diagnostic…
